Clinicopathologic Features of Membranous-Like Glomerulopathy With Masked IgG Kappa Deposits

por Larsen, C.P., Boils, C.L., Cossey, L.N., Sharma, S.G., Walker, P.D.
Publicado 2016

Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly

por Vincenti, F., Blancho, G., Durrbach, A., Grannas, G., Grinyó, J., Meier‐Kriesche, H.‐U., Polinsky, M., Yang, L., Larsen, C. P.
Publicado 2017

De novo donor‐specific antibodies in belatacept‐treated vs cyclosporine‐treated kidney‐transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT‐EXT...

por Bray, R. A., Gebel, H. M., Townsend, R., Roberts, M. E., Polinsky, M., Yang, L., Meier‐Kriesche, H.‐U., Larsen, C. P.
Publicado 2018

Posttransplant reduction in preexisting donor‐specific antibody levels after belatacept‐ versus cyclosporine‐based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT‐EXT...

por Bray, R. A., Gebel, H. M., Townsend, R., Roberts, M. E., Polinsky, M., Yang, L., Meier‐Kriesche, H.‐U., Larsen, C. P.
Publicado 2018

Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT‐EXT at 7 Years After Transplant

por Florman, S., Becker, T., Bresnahan, B., Chevaile‐Ramos, A., Carvalho, D., Grannas, G., Muehlbacher, F., O'Connell, P. J., Meier‐Kriesche, H. U., Larsen, C. P.
Publicado 2016

ALEFACEPT PROMOTES COSTIMULATION BLOCKADE BASED ALLOGRAFT SURVIVAL IN PRIMATES

por Weaver, T.A., Charafeddine, A.H., Agarwal, A., Turner, A.P., Russell, M., Leopardi, F.V., Kampen, R.L., Stempora, L., Song, M., Larsen, C.P., Kirk, A.D.
Publicado 2009